Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT06344767
- Lead Sponsor
- Fudan University
- Brief Summary
To investigate the treatment pattern and efficacy of patients with negative primary ER lesion but positive ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 19
Inclusion Criteria
- Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a nonmetastatic stage.
- MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2012 and 2023
- Patients diagnosed with primary ER-negative tumor and who were yet to receive any systemic therapy during the advanced stage
Exclusion Criteria
Patients with incomplete medical records and those diagnosed with secondary primary tumors
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival (PFS) 6 weeks Progression free survival
- Secondary Outcome Measures
Name Time Method Adverse events 6 weeks Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0
Trial Locations
- Locations (1)
China,Shanghai
🇨🇳Shanghai, Shanghai, China